Category Archives: GLP-1RA

Novo Initiates NLPR3i Obesity Study; Rani Partners with China-based Biotech Drug Delivery; Pfizer Gets New Head of Obesity Discovery; Novo Sponsors Athletes at Wimbledon

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Rani Therapeutics/PegBio, and Pfizer. Below, FENIX provides highlights and insight for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Hengrui Ph2 Triple Agonist Study; MindRank Series B; Semaglutide on NEDL; New Foundayo DTC Ad; Endogenex ReCET Enrollment Complete; Ionis/AZ Miss Primary Endpoint in CARDIO-TTRansform; Dr. Reddy’s Halts Sema

A series of cardiometabolic-related news items has been observed by Hengrui, MindRank, Lilly, Endogenex, Ionis/AstraZeneca, and Dr. Reddy’s. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Vivani + Novo Partner for Sema Implant; Kailera Ph3 Oral Obesity and T2DM Data; TIXiMED Ph1b MAD Study; ESC 2026 Hot Line Sessions

A series of cardiometabolic-related news items has been observed from Vivani Medical/Novo Nordisk, Kailera Therapeutics, TIXiMED, and European Society of Cardiology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany Launch

A series of cardiometabolic-related news items has been observed from AstraZeneca/CSPC Pharmaceutical, Amgen, Ascletis Pharma, Regeneron Pharmaceuticals, Trinity Biotech, MHRA, Adocia, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Ph1b Elora + Tirzep Preliminary Data; Ribo and Madrigal First siRNA Development Milestone; UpDoc FDA Clearance

Three cardiometabolic-related news items have been observed: Lilly released preliminary data from its Ph1b eloralintide + tirzepatide combination study (view abstract), Ribo and Madrigal reached the first milestone in their MASH siRNA partnership (view press release), and UpDoc received FDA clearance for its physician-grade clinical AI platform (view press release ). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs

A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet Appoints Chief R&D Officer; FDA to Review Sandoz Generic Tirzepatide; Kailera Appoints Chief Affairs Officer; Resalis Doses First Patient in Ph1b Obesity Study

A series of cardiometabolic-related news items have been observed from Insulet, FDA/Sandoz, Kailera Therapeutics, and Resalis Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

June CHMP Meeting Highlights; New Enicepatide China-Based Ph3 Obesity Study; Cirius Initiates Ph2 Dosing in T1DM Study

Three cardiometabolic-related news items have been observed: The CHMP highlights for this month’s meeting (June 22-25) have been released (view highlights), Roche initiated a new Ph3 China-based enicepatide obesity study (view CT.gov record), and Cirius Therapeutics initiated enrollment and dosing in its Ph2 T1DM study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo AMAZE 7 and 13 Zenagamtide Studies; New Ph2 UBT251 Study; Vivani Ph1 Sema Implant Study; TWL Virtual Tirzepatide Assessment; Anodyne $12.6M Series A

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Vivani Medical, Top Weight Loss Med, and Anodyne Nanotech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Viking Ph1 DACRA Study; Lilly Collaborates with Oura; Pivot Patch Pump US Launch; Wave Initiates Ph2a MAD INLIGHT Study; Wegovy FlexTouch Label Update; Tryngolza sHTG US Approval

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Lilly/Oura, Modular Medical, Wave Life Sciences, Novo Nordisk, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here